The question is whether IP-10 is sufficiently specific to differentiate between the clinical entities of active smear-negative TB, EPTB and LTBI, which is a common dilemma also in our setting with TB suspects mainly originating from TB high endemic areas. This evidence concerns the gene CXCL10 and tuberculosis.